Intellia Q3 net loss $135.7M; cash $944.7M; FDA clears Phase 3 for nex-z polyneuropathy

Intellia Therapeutics, Inc.

2024-Q3 EPS reported -$3.99 revenue$45,003,000

Net loss $135.7M vs $122.2M YoY; cash $944.7M (down from $1.0B at Dec 31).
FDA IND clearance for MAGNITUDE-2 Phase 3 trial of nex-z for ATTRv polyneuropathy; enrollment on track by year-end.
MAGNITUDE Phase 3 (ATTR-CM) enrollment tracking ahead; HAELO Phase 3 (HAE) actively screening.
Positive Phase 2 data for NTLA-2002: 8/11 patients attack-free after single 50mg dose; no serious AEs.
On track to dose first patient in NTLA-3001 Phase 1/2 for AATD by year-end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.